CLL Coverage from Every Angle

FDA Brief: New Drug Application Accepted for CD20-Targeted CAR T-Cell Therapy for CLL

By: JNCCN 360 Staff
Posted: Monday, May 17, 2021

On May 10, Mustang Bio announced that the U.S. Food and Drug Administration (FDA) accepted an investigational new drug application to start a phase I/II multicenter clinical trial to investigate MB-106. This new agent is a CD20-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory CD20-positive chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma.

MB-106 is currently being studied in an ongoing phase I/II study, where it has shown a reportedly favorable safety profile, with an 89% overall response rate and a 44% complete response rate.

The new multicenter study will be studying the safety, tolerability, and efficacy of MB-106. The enrollment period is expected to begin in the third quarter of this year.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.